Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Sònia Palomeras"'
Autor:
Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-16 (2019)
Abstract Background Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim o
Externí odkaz:
https://doaj.org/article/c46e786b11a64f6da3455d65e4742588
Publikováno v:
Molecules, Vol 23, Iss 9, p 2193 (2018)
Despite advances in breast cancer diagnosis and treatment, many patients still fail therapy, resulting in disease progression, recurrence, and reduced overall survival. Historically, much focus has been put on the intrinsic subtyping based in the pre
Externí odkaz:
https://doaj.org/article/ec1cfe50938545d18ac2b9db689d14a0
Autor:
Joan Crous-Masó, Sònia Palomeras, Joana Relat, Cristina Camó, Úrsula Martínez-Garza, Marta Planas, Lidia Feliu, Teresa Puig
Publikováno v:
Molecules, Vol 23, Iss 5, p 1160 (2018)
(−)-Epigallocatechin 3-gallate (EGCG) is a natural polyphenol from green tea with reported anticancer activity and capacity to inhibit the lipogenic enzyme fatty acid synthase (FASN), which is overexpressed in several human carcinomas. To improve t
Externí odkaz:
https://doaj.org/article/47da1200e79b4a37938d1d194c1eb1e1
Autor:
Adriana Blancafort, Ariadna Giró-Perafita, Glòria Oliveras, Sònia Palomeras, Carlos Turrado, Òscar Campuzano, Dolors Carrión-Salip, Anna Massaguer, Ramon Brugada, Marta Palafox, Jorge Gómez-Miragaya, Eva González-Suárez, Teresa Puig
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131241 (2015)
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical H
Externí odkaz:
https://doaj.org/article/d0946f7276224e738d25e57de6ec46aa
Autor:
Sònia Palomeras, Marc Rabionet, Inés Ferrer, Ariadna Sarrats, Maria Luisa Garcia-Romeu, Teresa Puig, Joaquim Ciurana
Publikováno v:
Molecules, Vol 21, Iss 4, p 537 (2016)
The cancer stem cell (CSC) population displays self-renewal capabilities, resistance to conventional therapies, and a tendency to post-treatment recurrence. Increasing knowledge about CSCs’ phenotype and functions is needed to investigate new thera
Externí odkaz:
https://doaj.org/article/1580c29162c84aee9bd4cdb29e606c5e
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of doxorubicin (50 - 350 nM) for 48h. Experiments were performed three times in triplicate. Results shown are mean {plus minus} SEM. *(p < 0.05), **(p < 0.01)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a0dc4a12d2701027c6a56bd1d40df5d
https://doi.org/10.1158/1078-0432.22462608
https://doi.org/10.1158/1078-0432.22462608
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
cells (A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with increasing concentrations of cetuximab (0,5 - 4 µM), C75 (20 - 60 µM) or EGCG ( 25 - 150 µM) for 4 days. Results are expressed as mean {plus minus} SEM. Experiments were perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d1b348f65d50d103597c45b45fc82a0
https://doi.org/10.1158/1078-0432.22462596
https://doi.org/10.1158/1078-0432.22462596
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) 231 and 231DXR and (B) HCC and HCCDXR cells were treated with doxorubicin (50-100-150nM) and C75 (20µM for HCC, HCCDXR; 40µM for 231, 231DXR) or the combination for 48h. (C) 231 and 231DXR and (D) HCC and HCCDXR cells were treated with doxorubi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443258cd2e2ece25708066dba734bd8f
https://doi.org/10.1158/1078-0432.22462599
https://doi.org/10.1158/1078-0432.22462599
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
Purpose: Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse within 5 years after treatment. EGFR overexpression is a common marker in TNBC, and its expre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f535db6bd8c240075c66dde3cf919cf
https://doi.org/10.1158/1078-0432.c.6525147.v1
https://doi.org/10.1158/1078-0432.c.6525147.v1
Autor:
Teresa Puig, Alana L. Welm, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Gemma Viñas, Adriana Blancafort, David H. Lum, Sònia Palomeras, Ariadna Giró-Perafita
(A) Mice bearing 231 and (B) 231DXR xenografts were treated with saline (Control), EGCG (30mg/Kg, 3 days a week), cetuximab (0.5mg/mice 1 day a week) or the combination (EGCG plus cetuximab) for 12 days. (C) Mice bearing HCC and (D) HCCDXR xenografts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::766d33ef3b26308bb1bff159b038f209
https://doi.org/10.1158/1078-0432.22462593
https://doi.org/10.1158/1078-0432.22462593